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                Dean’s Newsletter
School of Medicine
Center for Cell Analysis 
and Modeling – Home of 
the Virtual Cell
Education
More than 2,000 scientists from around the world – and counting – have 
utilized a computer software 
and database system created 
and housed at the UConn 
Health Center to construct 
computational models of cells. 
Called the Virtual Cell, it also 
performs simulations to analyze 
the results of those simulations 
to better understand cell 
physiology. In this issue, we 
will introduce you to Dr. Leslie 
Loew, director of the UConn 
Health Center’s Richard D. Berlin 
Center for Cell Analysis and 
Modeling, and the impressive 
work his multidisciplinary team 
is producing. 
 Dr. Loew, together with 
a cadre of elite researchers 
from several other bioscience 
departments, recently moved 
into the new, state-of-the-art 
Cell and Genome Sciences 
Building, adjacent to our 
campus. The building’s award-
winning design was created to 
encourage cross-disciplinary 
collaborations and innovations. 
Of note, the building also 
includes incubator space for 
emerging bioscience industries 
which was fully leased within 
the first year of occupancy.  
Dean’s Message
UConn School of Medicine
A novel imaging device developed at the University of  Connecticut is showing favorable results in an  expanded clinical trial and could 
significantly reduce physicians’ reliance 
on breast biopsies. 
 The device, which uses 
ultrasound-guided diffuse optical 
tomography (DOT) to locate 
and analyze suspicious tumors in 
breast tissue, was tested on 178 
women over a four-year period 
from 2004 to 2008. The study was 
supported by the National Institutes 
of Health and the Donaghue Medical 
Research Foundation. Testing was 
conducted among patients between the 
ages of 21 and 89 at the UConn Health Center 
and Hartford Hospital. 
 The study showed that the device had a reliability rate of 92 
percent in terms of sensitivity and 93 percent in terms of specificity 
when evaluating smaller cancers less than 2 centimeters in size. The 
results of the study have been published in the journal Radiology, 
published by the Radiological Society of North America. 
 “Based on our results, we believe DOT holds promise as 
an adjunct to diagnostic mammography and ultrasound for 
distinguishing early-stage invasive breast cancers from benign 
lesions,” says Quing Zhu, Ph.D., a professor in the Department of 
Electrical and Computer Engineering. Zhu has been working with 
graduate students in the School of Engineering and Health Center 
physicians over the past decade to refine and test the device. 
 “We expect this technology will be used to help radiologists 
evaluate small- to intermediate-sized lesions that are harder 
to diagnose with conventional imaging technologies,” Zhu 
says. “We will not completely eliminate biopsies. No 
modality is perfect. But we want to improve existing 
imaging technology so a better diagnosis can be made.” 
 In the UConn study, women who had 
suspicious lesions in their breasts were first analyzed 
with DOT and then given a needle biopsy. The 
results of each test were then correlated to judge the 
sensitivity and specificity of the DOT. Zhu says the 
DOT found both maximum and average total hemoglobin 
levels were significantly higher in the malignant groups than 
in the benign groups of tissue samples, proving the device’s 
effectiveness. Laboratory examination of the tissue samples 
revealed two in situ carcinomas, 35 carcinomas that measured less 
than 2 centimeters, 24 carcinomas greater than 2 centimeters, and 
114 benign lesions.  
 The DOT device has been patented. “The next step is to 
develop multi-institution prospective clinical trials to further 
evaluate the device’s effectiveness,” Zhu says. Collaborating with 
Zhu on the study were Poornima Hegde, M.D., Mark Kane, 
M.D., Susan Tannenbaum, M.D., Peter Deckers, M.D., and Scott 
Kurtzman, M.D., from the UConn Health Center and Edward 
Cronin, M.D., Andrew Ricci Jr., M.D., and Patricia DeFusco, 
M.D., from Hartford Hospital. n
Clinical Trials Favorable for Novel Breast Cancer Detection Device
The Cell and Genome Sciences 
Building was dedicated earlier 
this year (see photo on back 
page), heralding in a new era of 
growth in bioscience research 
and job creation. We look 
forward to sharing updates  
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UConn Cardiologists 
Uncover New Heart 
Attack Warning Sign
Health Center cardiologists, led by Bruce Liang, M.D., F.A.C.C., director of the Pat and Jim Calhoun 
Cardiology Center, have identified a 
protein fragment that when detected in 
the blood can be a predictor of heart 
attack. Their research was published 
in a recent issue of the Journal of the 
American College of Cardiology. It found 
that heart attack patients had elevated 
levels of the protein fragment known as 




“We’ve discovered a new biomarker for 
heart attack and showed that apoptosis 
is a cause of heart muscle damage,” 
Liang says. “The ability to see a heart 
attack coming with a simple blood test 
and to develop new therapies to block 
apoptosis would enable us to get a head 
start on treatment and preserve crucial 
heart muscle and cardiac function.” 
 “This test can work in patients but 
has not met regulatory requirements 
for clinical application in patients 
suspected of having a heart attack,” 
Liang says. “If it is successfully applied 
one day, it would mean another way to 
diagnose heart attack and the possible 
development of new treatments.”
 
 Co-investigators include Mariela 
Agosto, M.D., Michael Azrin, M.D., and 
Kanwar Singh, M.D., F.A.C.C., from the 
UConn Health Center and Allan Jaffe, 
M.D., from the Mayo Clinic and Mayo 
Medical School in Rochester, Minn. n
Research
Barbara E. Kream, Ph.D., has been appointed the associate dean of the 
Graduate School. A professor 
of Medicine and Genetics and 
Developmental Biology, she 
holds a joint appointment as 
professor in the Department of 
Orthopaedic Surgery. Kream 
has been active with student 
training and mentoring and is 
a long-standing member of the 
Biomedical Science and Dental 
Science Graduate faculty. She 
currently is the director of the 
M.D./Ph.D. program. n
The Hartford Medical Society Historical Library at the UConn 
Health Center has its 
first five titles digitized 
and available for viewing 
through the Internet 
Archive, a digital library 
found at www.archive.org 
that offers free access to 
books and other materials. 
Touching on a range of 
unexpected topics, these 
newly digitized titles from 
the 19th century include 
such peculiar titles as 
Human Monstrosities, 
Pathology of Drunkenness, 
and Observations on the 
Management of Madhouses. 
To see the full list and access 
the digitized volumes visit 
http://uchc.libguides.com/
hms. n
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The 19 th Century 
Goes Digital
New Leader for 
Graduate School
Uncovering the Mysteries 
of Human Cells  
 
E ach of the 100 trillion cells in the human body is a tiny parcel of water and chemicals containing the entire human genome – all of the DNA that an individual possesses. For Leslie 
Loew, Ph.D., and his team of researchers, uncovering the mysteries 
of these cells and how they behave in the body is a mission, a 
fascination, a pursuit that can lead to a better understanding of 
diseases and how best to treat them. 
 Loew, a professor of cell biology as well as computer science 
and engineering, is the director of the UConn Health Center’s 
Richard D. Berlin Center for Cell Analysis and Modeling (CCAM). 
Loew and fellow researchers at CCAM are developing new 
approaches to determine how cells work, interact, and respond – 
and how to organize this data so it can be applied to human health. 
 CCAM integrates state-of-the-art microscope technologies with 
computational tools that produce realistic models of cell dynamics. 
The innovative work performed at CCAM has received worldwide 
attention and millions in annual grant support since the Center 
was established in 1994. 
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Bringing together biomedical researchers 
from various disciplines, CCAM provides a 
setting that supports and reinforces the value 
of collaboration. “Our Center is unique in that 
we have chemists, physicists, mathematicians, 
biologists, and computer scientists all 
working together,” Loew says. “We were far 
ahead of our time when we started these 
interdisciplinary groups.” 
 It is also the home of the Virtual Cell, 
a computerized environment that allows 
scientists to simulate the inner workings of 
cells. With the Virtual Cell, investigators can 
build intricate models using a web-based 
interface in order to evaluate hypotheses, 
interpret data, or probe the predicted behavior 
of complex systems. 
 Designated and funded as a National 
Resource by the National Institutes of Health 
(NIH), the Virtual Cell is available for free via 
the Internet as a tool for scientists and other 
members of the scientific community. 
 “More than 2,000 labs around the world 
are using the Virtual Cell,” Loew says. “The 
NIH grant mandates that we continue building 
software to support it and to make sure there is 
access to it.” 
 
Research in Progress
Loew’s team at CCAM is currently partnering on a project with the Mount Sinai School of Medicine and Columbia 
University to determine how human kidney 
cells are regulated to produce the delicate 
filtration system that allows the kidney to 
function. The project has been awarded a 
five-year, $6 million grant from the NIH’s 
Transformative Research Project Program, 
which supports innovative research with the 
potential for major impact on human health. 
In this study, the Virtual Cell is being used  
to develop computational models of how  
cells interact within kidney tissues. 
Ultimately, its results could aid scientists 
in understanding disease processes and in 
screening for new drugs. 
 Another example of current Virtual Cell 
research is a study by M.D./Ph.D. candidate 
Sherry-Ann Brown that examines the way 
in which signals in the brain are transferred 
across synapses and neurons. Genetic defects 
in these biochemical pathways are linked 
to ataxia, which impacts an individual’s 
motor coordination, speech, handwriting, 
and balance. Such research could lead to a 
better understanding of brain cell function – 
resulting in advances in prevention, diagnosis, 
and treatment. 
 CCAM provides a vast array of laboratory 
equipment that can be used for obtaining 
experimental data needed to create and 
enhance Virtual Cell models. Among CCAM’s 
$8 million in major equipment are confocal 
and laser optical microscopes, multiprocessor 
computers, and spectrometers that use light to 
study matter. 
 The Center recently moved to the new 
Cell and Genome Sciences Building, which 
was designed to promote interdisciplinary 
research in a wide range of projects. In 
addition to CCAM, the building also 
houses the UConn Stem Cell Institute, the 
Department of Genetics and Developmental 
Biology, and UConn’s Office of Technology 
Commercialization (including the Technology 
Incubation Program – UConn’s business 
incubator), enhancing the University’s role as 
a leader in innovative research and technology 
in these areas. 
 CCAM, and especially the Virtual Cell, 
is the culmination of decades of work for 
Loew, who began his career in an academic 
chemistry department. “Some of 
the technology I was developing 
could be applied to asking 
questions about how cells 
behave,” he says of his research. 
“It soon became clear to me 
that I was only going to enjoy 
developing these tools if I could 
use them myself.” n
“Our Center is unique in that 
we have chemists, physicists, 
mathematicians, biologists, 
and computer scientists all 
working together.”
    Les Loew, Ph.D., director of CCAM 
Erick Avelar, M.D., (left) and a Health Center 





The Pat and Jim Calhoun Cardiology Center has been 
invited to be a test site for a 
groundbreaking clinical trial. 
The National Institutes of 
Health is studying the use of 
cardiac imaging to diagnose 
problems associated with chest 
pain, the most common clinical 
cardiology problem. 
 The PROspective Multicenter 
Imaging Study for the Evaluation 
of Chest Pain, or PROMISE, is 
the first randomized imaging 
trial in the history of cardiology. 
It seeks to enroll 10,000 
patients at more than 200 sites 
throughout the U.S. The UConn 
Health Center was the first site 
in Connecticut to join the study, 
with Erick Avelar, M.D., director 
of noninvasive cardiac imaging, 
serving as principal investigator. 
 “Computed tomography of 
the coronary artery, also known 
as a cardiac CT, is hypothesized 
to yield better results than 
functional testing such as an 
EKG or stress test, but it is not 
the current standard of care 
and generally not covered by 
insurance,” Avelar says.  
 The targeted study 
population consists of chest 
pain patients with low to 
intermediate probability of 
significant obstructive coronary 
artery disease, including men 55 
and older and women 65 and 
older. Men as young as 45 and 
women as young as 50 also may 
be eligible, depending on their 
individual risk factors. n
x
Ann Cowan, Ph.D., deputy director of CCAM.
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Gift to Support Stem  
Cell Research
In appreciation for committing $700,000 to support stem cell research, the Edmund and Arlene Grossman 
Auditorium was dedicated in their honor 
during the Cell and Genome Sciences 
Inaugural Symposium this past December. 
 “The University of Connecticut has been a 
national leader in the area of stem cell research, 
and the generous support of Edmund and Arlene 
Grossman will help us immeasurably to expand our work 
in this vital area,” says University of Connecticut interim 
president Philip E. Austin. “Our faculty’s research in this field 
is emblematic of the University’s role in expanding the frontiers 
of knowledge in areas of critical importance to the people of 
Connecticut and far beyond.”  
 The Grossmans, both cancer survivors, want to support 
research that has the greatest potential to treat and cure diseases 
such as Parkinson’s and Alzheimer’s, which have affected close 
friends of theirs, as well as cancer.  
 “This is such an incredible time in medical research that 
it behooves those of us who can to provide for the gains. The 
implications are mind-boggling. The good that could be done 
with stem cell research far outstrips anything else we could do 
to help mankind,” says Mr. Grossman. 
 “Ed and Arlene Grossman share our vision and believe in 
our promise to be a world leader in stem cell research. Their 
support will help us attract preeminent faculty and translate 
discoveries made in the lab into new therapies and cures,” says 
Marc Lalande, Ph.D., director of the Stem Cell Institute and 
senior associate dean for research planning and coordination at 
the UConn Health Center. n
 
Cancer Center Director Appointed 
Pramod K. Srivastava, Ph.D., M.D., an accomplished leader in basic and 
translational research, has 
been named the new director 
of the Carole and Ray Neag 
Comprehensive Cancer Center. 
    Srivastava is a professor and 
interim chair of the Department 
of Immunology, director of the 
Center for Immunotherapy of 
Cancer and Infectious Diseases, 
and part of the leadership team 
of the Connecticut Institute 
for Clinical and Translational 
Science. He holds the Physicians Health Services Chair in 
Cancer Immunology. 
 He has earned international acclaim for his groundbreaking 
work in the immunological function of heat shock proteins 
and in cancer immunology, is widely published in scholarly 
journals, and serves on editorial boards for several major 
journals in immunology. n 
New Academic Chair Announced
Royce Mohan, Ph.D., a scientist and educator who specializes in tissue 
repair of the eye, has joined 
the UConn Health Center 
as the John A. and Florence 
Mattern Solomon Chair 
in Vision Biology and Eye 
Diseases. 
 Mohan, who has a Ph.D. 
in biochemistry from Ohio 
State University, was most recently an associate professor in 
the Department of Ophthalmology and Visual Sciences at 
the University of Kentucky. He won acclaim at Kentucky for 
a discovery that holds the potential for new treatments for 
diseases of the brain, spinal cord and eye.  
 Florence Solomon, one of the chair’s donors, suffers from 
macular degeneration, a focus of Mohan’s research. Mohan, 
mentored at Yale University in chemical genetics and inspired 
by pioneer Judah Folkman of Harvard Medical School, brings 
a distinctive mark to anti-angiogenesis and anti-fibrosis 
therapeutic research. n 
 
1,264,919 Number of visits to 
the Health Center’s Lyman Maynard Stowe
Library – 1,057,474 virtual visits from 
homes or offices, and 197,445 in person
Fast Fact 
UConn Cardiologist 1st in New England  
with New Treatment
K anwar Singh, M.D., F.A.C.C., an interventional 
cardiologist in the Pat and 
Jim Calhoun Cardiology 
Center, is the first physician 
in the region to take an 
innovative, minimally 
invasive approach to treating 
peripheral arterial disease. 
 Using a new device 
called the Wildcat catheter, 
Singh was able to reopen a 
completely blocked artery 
in a patient’s leg through a 
2-millimeter skin incision. 
 Some blockages are 
severe and difficult to pass through with traditional catheters, 
forcing patients to undergo more invasive bypass surgery 
and subjecting them to higher risks and prolonged recovery. 
In those cases where the plaque deposits cannot be passed, 
patients face an increased possibility of losing a limb to 
amputation. This minimally invasive alternative to bypass 
surgery enables patients to leave the hospital within hours  
and return to normal activities within a few days.  
 “The Wildcat catheter was developed by Avinger, Inc.,  
who approached us,” Singh says. “They know we are doing 
truly advanced work here in vascular disease and wanted 
to partner with us early in the rollout of this new device. 
Amazingly, as advanced as the Wildcat catheter already is, 
the future generations of this tool will incorporate a forward-
looking imaging component that may be the next quantum 
leap in vascular disease, so it’s really exciting to be a part of  
this program.” n 
UConn Health Center Celebrates 50th 
Anniversary with White Coat Gala  
Part of the yearlong celebration of the UConn Health Center’s founding included the festive White Coat gala this spring.  
 With more than 800 people in attendance, funds were 
raised to support faculty and researchers throughout the 
institution. During the event, three leaders who have played 
vital roles in the history of the Health Center were honored: 
 Marja Hurley, M.D., is an internationally prominent 
molecular biologist and endocrinologist who has served the 
Health Center for 25 years. She directs the Health Career 
Opportunity Programs, and is currently serving as the medical 
school’s interim senior associate dean for education.  
 Ravindra Nanda, B.D.S, M.D.S., Ph.D., is a renowned 
leader in orthodontics who joined the Health Center in 1972. 
He is the UConn Orthodontic Alumni/Ravi Nanda Chair in 
Orthodontics and head of the Division of Orthodontics and  
the Department of Craniofacial Sciences.  
 Basketball Hall of Fame Coach Jim Calhoun is a long-
standing and generous donor. All told, he and his wife Pat have 
helped raise nearly $3 million to support the Health Center’s 
cancer and cardiology programs. n
Front row, left to right: Title Sponsor Richard Lublin; Ray Neag; Carole Neag; Honoree 
Dr. Marja Hurley; Pat Calhoun; Honoree Dr. Ravi Nanda; Catherine Nanda. 
Back row, left to right: Dental School Dean Dr. Monty MacNeil; Lee MacNeil; Honoree 
Jim Calhoun; Vice President for Health Affairs Dr. Cato T. Laurencin; Cynthia Laurencin; 
John Hurley.
Dr. Kanwar Singh shows cardiology nurse 
Cathy Ingriselli the Wildcat catheter. 
Inside the Grossman Auditorium.




Gift to Support Stem  
Cell Research
In appreciation for committing $700,000 to support stem cell research, the Edmund and Arlene Grossman 
Auditorium was dedicated in their honor 
during the Cell and Genome Sciences 
Inaugural Symposium this past December. 
 “The University of Connecticut has been a 
national leader in the area of stem cell research, 
and the generous support of Edmund and Arlene 
Grossman will help us immeasurably to expand our work 
in this vital area,” says University of Connecticut interim 
president Philip E. Austin. “Our faculty’s research in this field 
is emblematic of the University’s role in expanding the frontiers 
of knowledge in areas of critical importance to the people of 
Connecticut and far beyond.”  
 The Grossmans, both cancer survivors, want to support 
research that has the greatest potential to treat and cure diseases 
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friends of theirs, as well as cancer.  
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discoveries made in the lab into new therapies and cures,” says 
Marc Lalande, Ph.D., director of the Stem Cell Institute and 
senior associate dean for research planning and coordination at 
the UConn Health Center. n
 
Cancer Center Director Appointed 
Pramod K. Srivastava, Ph.D., M.D., an accomplished leader in basic and 
translational research, has 
been named the new director 
of the Carole and Ray Neag 
Comprehensive Cancer Center. 
    Srivastava is a professor and 
interim chair of the Department 
of Immunology, director of the 
Center for Immunotherapy of 
Cancer and Infectious Diseases, 
and part of the leadership team 
of the Connecticut Institute 
for Clinical and Translational 
Science. He holds the Physicians Health Services Chair in 
Cancer Immunology. 
 He has earned international acclaim for his groundbreaking 
work in the immunological function of heat shock proteins 
and in cancer immunology, is widely published in scholarly 
journals, and serves on editorial boards for several major 
journals in immunology. n 
New Academic Chair Announced
Royce Mohan, Ph.D., a scientist and educator who specializes in tissue 
repair of the eye, has joined 
the UConn Health Center 
as the John A. and Florence 
Mattern Solomon Chair 
in Vision Biology and Eye 
Diseases. 
 Mohan, who has a Ph.D. 
in biochemistry from Ohio 
State University, was most recently an associate professor in 
the Department of Ophthalmology and Visual Sciences at 
the University of Kentucky. He won acclaim at Kentucky for 
a discovery that holds the potential for new treatments for 
diseases of the brain, spinal cord and eye.  
 Florence Solomon, one of the chair’s donors, suffers from 
macular degeneration, a focus of Mohan’s research. Mohan, 
mentored at Yale University in chemical genetics and inspired 
by pioneer Judah Folkman of Harvard Medical School, brings 
a distinctive mark to anti-angiogenesis and anti-fibrosis 
therapeutic research. n 
 
1,264,919 Number of visits to 
the Health Center’s Lyman Maynard Stowe
Library – 1,057,474 virtual visits from 
homes or offices, and 197,445 in person
Fast Fact 
UConn Cardiologist 1st in New England  
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innovative, minimally 
invasive approach to treating 
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Singh was able to reopen a 
completely blocked artery 
in a patient’s leg through a 
2-millimeter skin incision. 
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Connecticut Governor Dannel Malloy takes part in a ceremonial ribbon cutting with elected officials, University trustees and directors, and researchers at the newly renovated Cell and 
Genome Sciences Building. Equipped with the latest technologies, 
the nearly 120,000-square-foot research facility has united 
University scientists in accelerating discoveries  
that ultimately could lead to novel  
therapies treating a broad  
range of diseases.
